The objective of this study was to conduct a comparative study of different etiologies of neurogenic bladder disorders (NBDs) in patients with bladder cancer (BC) regarding patient- and tumor-related parameters and their oncological outcome.
The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC).
While various surgical techniques have been reported for open and minimally invasive treatment of upper tract urothelial cancer (UTUC), the procedure of robot-assisted nephroureterectomy (NU) with bladder cuff has never been reported using only retroperitoneum without entering abdominal cavity.
Dr. Rodolfo Hurle and co-workers showed, in their phase I multicentric international study, that Oncofid-P-B development by Fidia Farmaceutici S.p.A. (Italy), may be considered an innovative compound for the treatment of high-risk and very high-risk nonmuscle-invasive bladder cancer (NMIBC).1 Oncofid-P-B results from the chemical conjugation of paclitaxel with hyaluronic acid (HA). HA has been studied for […]
Charles Ryan: Hi and welcome. I am delighted to be joined today by a friend and colleague, Stuart Bloom. Stuart is an associate professor of medicine at the University of Minnesota, where I work. And he’s a medical oncologist with a very interesting background and an ongoing program looking at physician burnout. So we’re going […]
Studies are Key Next Step Toward FDA Discussions on Potential OTC Labelling Status San Francisco, CA (UroToday.com) — Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men’s health, has initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA® (avanafil). The results of these studies will be part of a more comprehensive data package the […]
Background: Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer. This individual patient data meta-analysis of relevant randomised trials aimed to quantify the benefit of these interventions in aggregate and in clinically relevant subgroups.
While the EAU and the European Board of Urology (EBU) have to maintain a formal distance when it comes to accrediting events and education, there is also scope for the two bodies to collaborate, says the EBU’s new President, Prof. Jeroen Van Moorselaar (Amsterdam, NL). “Collaboration can come in small things,” says Prof. Van Moorselaar, […]
Highlights Complete response is the de facto primary endpoint for NAC trials in locally advanced UC. Residual CIS-only after NAC and RC had similar survival to patients with complete response in a large cohort. Residual CIS-only may be considered for inclusion as an endpoint for survival in NAC trials. CR as the sole endpoint in […]
Highlights Upper tract urothelial carcinoma is notoriously difficult to accurately stage Risk stratification of patients prior to surgery remains a challenge We developed preoperative nomograms to quantitatively predict muscle-invasive disease and lymph node metastasis in UTUC Accuracy of the nomograms were 80.0% and 87.8% respectively This information could be helpful for preoperative risk assessment and […]
